Clinical Trials Browser

Not yet recruiting × Genitourinary × Clear all

NCT06982222 2026-03-18

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Phase 1 Not yet recruiting

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT07480044 2026-03-18

A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery

Phase NA Not yet recruiting

Emergence Delirium, Carcinoma, Renal Cell, Prostatic Neoplasms

NCT07480356 2026-03-18

ADVANCED-3

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT07322263 2026-03-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07470840 2026-03-17

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Phase 2 Not yet recruiting

Muscle Invasive Bladder Cancer (MIBC)

NCT07475806 2026-03-17

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Not yet recruiting

Muscle-invasive Bladder Cancer

NCT07476677 2026-03-17

ANDARP

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07478536 2026-03-17

CHAS3

Not yet recruiting

Neoplasms, Prostatic Neoplasms

NCT07419841 2026-03-16

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Phase 1 Not yet recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Endometrial Neoplasms

NCT07465458 2026-03-16

RASROP-003

Not yet recruiting

Carcinoma, Renal Cell

NCT07468838 2026-03-16

UroDNA

Not yet recruiting

Urinary Bladder Neoplasms, Prostatic Neoplasms

NCT07475533 2026-03-16

Low-flow Versus Minimal-flow Sevoflurane Anesthesia During Robot-assisted Laparoscopic Radical Prostatectomy

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT06963970 2026-03-13

PATH

Phase NA Not yet recruiting

Dementia, Kidney Diseases, Lung Diseases, Obstructive, Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07463092 2026-03-13

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

Phase NA Not yet recruiting

Prostatic Neoplasms, Sarcopenia

NCT07468851 2026-03-13

A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

Phase 1/2 Not yet recruiting

High-risk Non-muscle-invasive Bladder Cancer

NCT07468903 2026-03-13

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07140315 2026-03-12

DK222 Study at Hopkins

Phase 1 Not yet recruiting

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07296887 2026-03-12

CARE Tool Study Aim 3

Phase NA Not yet recruiting

GastrointestinalGenitourinaryThoracic

Financial Stress, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT07457164 2026-03-12

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

Phase 2 Not yet recruiting

Urogenital Diseases, Prostatic Diseases

NCT07468396 2026-03-12

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT07468708 2026-03-12

The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

Phase EARLY_PHASE1 Not yet recruiting

Prostatic Neoplasms

NCT07077083 2026-03-11

CAIX PET/CT

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07441837 2026-03-11

TeLuNa

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07463833 2026-03-11

Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation Oncology

Phase NA Not yet recruiting

Neoplasms, Prostatic Neoplasms

NCT07463963 2026-03-11

RUPTURE

Phase NA Not yet recruiting

Urinary Bladder Neoplasms

NCT07464145 2026-03-11

RESCUE

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT07460206 2026-03-10

PRELUDE

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07460245 2026-03-10

AVESEC

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT07460726 2026-03-10

PRIAPUS-PCa

Not yet recruiting

Adenocarcinoma, Erectile Dysfunction, Prostatic Neoplasms

NCT07454603 2026-03-06

PROSTest_STRAT

Not yet recruiting

Disease, Prostatic Neoplasms

NCT07455058 2026-03-06

VAPOR-LTR

Not yet recruiting

Prostatic Neoplasms

NCT07455903 2026-03-06

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07450599 2026-03-05

CHINANEO

Phase 2 Not yet recruiting

High-Risk Localized Prostate Cancer

NCT07297160 2026-03-04

CALySSEY

Phase 1 Not yet recruiting

GenitourinaryLymphoidOther hematologic neoplasmPlasma cellSarcoma

Kidney Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT07437482 2026-03-03

CLEAR-PC

Not yet recruiting

Disease, Prostatic Neoplasms

NCT07444983 2026-03-03

Rezvilutamide for High-Risk Prostate Cancer After Surgery

Phase NA Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07224009 2026-03-02

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07441889 2026-03-02

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Phase 1/2 Not yet recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06959433 2026-02-27

Lu-177 PSMA Treatment in Cell Renal Carcinoma

Phase 3 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06987045 2026-02-27

TransPRIDE

Not yet recruiting

Prostatic Neoplasms

NCT07123090 2026-02-27

SPARCC

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07243067 2026-02-27

Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer

Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07401875 2026-02-27

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

Phase 1 Not yet recruiting

Kidney Neoplasms

NCT07439120 2026-02-27

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Transitional Cell

NCT07440641 2026-02-27

RE-FIT

Phase NA Not yet recruiting

Motor Activity, Prostatic Neoplasms

NCT06834204 2026-02-25

ACCESS-PC

Phase NA Not yet recruiting

GenitourinaryGynecologic

Adenocarcinoma, Urinary Bladder Neoplasms, Diabetes Mellitus, Hypercholesterolemia, Hyperlipidemias, Hypertension, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT07406087 2026-02-25

Navigation Intervention for Adolescent and Young Adult Cancer Survivors

Phase NA Not yet recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms